|
Gene: GTF2H5 |
Gene summary for GTF2H5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GTF2H5 | Gene ID | 404672 |
Gene name | general transcription factor IIH subunit 5 | |
Gene Alias | C6orf175 | |
Cytomap | 6q25.3 | |
Gene Type | protein-coding | GO ID | GO:0000462 | UniProtAcc | Q6ZYL4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
404672 | GTF2H5 | GSM4909281 | Human | Breast | IDC | 1.22e-11 | 3.95e-01 | 0.21 |
404672 | GTF2H5 | GSM4909285 | Human | Breast | IDC | 5.31e-08 | 2.30e-01 | 0.21 |
404672 | GTF2H5 | GSM4909286 | Human | Breast | IDC | 1.95e-07 | 2.96e-01 | 0.1081 |
404672 | GTF2H5 | GSM4909288 | Human | Breast | IDC | 9.96e-03 | 2.07e-01 | 0.0988 |
404672 | GTF2H5 | GSM4909290 | Human | Breast | IDC | 7.70e-18 | 5.98e-01 | 0.2096 |
404672 | GTF2H5 | GSM4909291 | Human | Breast | IDC | 1.99e-03 | 3.21e-01 | 0.1753 |
404672 | GTF2H5 | GSM4909293 | Human | Breast | IDC | 9.76e-25 | 5.23e-01 | 0.1581 |
404672 | GTF2H5 | GSM4909294 | Human | Breast | IDC | 1.27e-30 | 7.44e-01 | 0.2022 |
404672 | GTF2H5 | GSM4909296 | Human | Breast | IDC | 5.56e-06 | -8.60e-02 | 0.1524 |
404672 | GTF2H5 | GSM4909297 | Human | Breast | IDC | 1.42e-07 | -5.91e-02 | 0.1517 |
404672 | GTF2H5 | GSM4909298 | Human | Breast | IDC | 8.64e-11 | 3.93e-01 | 0.1551 |
404672 | GTF2H5 | GSM4909299 | Human | Breast | IDC | 6.69e-03 | 2.33e-01 | 0.035 |
404672 | GTF2H5 | GSM4909301 | Human | Breast | IDC | 2.70e-09 | 4.29e-01 | 0.1577 |
404672 | GTF2H5 | GSM4909306 | Human | Breast | IDC | 3.73e-31 | 6.23e-01 | 0.1564 |
404672 | GTF2H5 | GSM4909307 | Human | Breast | IDC | 5.50e-12 | 4.04e-01 | 0.1569 |
404672 | GTF2H5 | GSM4909308 | Human | Breast | IDC | 1.08e-25 | 5.91e-01 | 0.158 |
404672 | GTF2H5 | GSM4909311 | Human | Breast | IDC | 2.96e-17 | -1.65e-01 | 0.1534 |
404672 | GTF2H5 | GSM4909312 | Human | Breast | IDC | 1.56e-04 | -6.81e-02 | 0.1552 |
404672 | GTF2H5 | GSM4909315 | Human | Breast | IDC | 2.26e-47 | 9.37e-01 | 0.21 |
404672 | GTF2H5 | GSM4909316 | Human | Breast | IDC | 2.08e-20 | 8.26e-01 | 0.21 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007147917 | Oral cavity | OSCC | cellular response to ionizing radiation | 49/7305 | 72/18723 | 5.59e-07 | 8.13e-06 | 49 |
GO:00063522 | Oral cavity | OSCC | DNA-templated transcription, initiation | 74/7305 | 130/18723 | 2.56e-05 | 2.39e-04 | 74 |
GO:00063601 | Oral cavity | OSCC | transcription by RNA polymerase I | 36/7305 | 55/18723 | 6.42e-05 | 5.22e-04 | 36 |
GO:00103326 | Oral cavity | OSCC | response to gamma radiation | 36/7305 | 56/18723 | 1.12e-04 | 8.24e-04 | 36 |
GO:00063672 | Oral cavity | OSCC | transcription initiation from RNA polymerase II promoter | 46/7305 | 77/18723 | 1.82e-04 | 1.24e-03 | 46 |
GO:0006289 | Oral cavity | OSCC | nucleotide-excision repair | 37/7305 | 60/18723 | 3.15e-04 | 1.96e-03 | 37 |
GO:00714809 | Oral cavity | OSCC | cellular response to gamma radiation | 21/7305 | 31/18723 | 1.13e-03 | 5.75e-03 | 21 |
GO:0070816 | Oral cavity | OSCC | phosphorylation of RNA polymerase II C-terminal domain | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
GO:0022613110 | Oral cavity | LP | ribonucleoprotein complex biogenesis | 259/4623 | 463/18723 | 7.20e-48 | 2.25e-44 | 259 |
GO:0042254110 | Oral cavity | LP | ribosome biogenesis | 173/4623 | 299/18723 | 8.97e-35 | 1.41e-31 | 173 |
GO:000636418 | Oral cavity | LP | rRNA processing | 134/4623 | 225/18723 | 6.08e-29 | 4.23e-26 | 134 |
GO:001607218 | Oral cavity | LP | rRNA metabolic process | 136/4623 | 236/18723 | 2.37e-27 | 1.48e-24 | 136 |
GO:003447014 | Oral cavity | LP | ncRNA processing | 184/4623 | 395/18723 | 1.20e-21 | 3.12e-19 | 184 |
GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
GO:0042274110 | Oral cavity | LP | ribosomal small subunit biogenesis | 48/4623 | 73/18723 | 1.42e-13 | 1.35e-11 | 48 |
GO:001021216 | Oral cavity | LP | response to ionizing radiation | 64/4623 | 148/18723 | 5.60e-07 | 1.51e-05 | 64 |
GO:007121417 | Oral cavity | LP | cellular response to abiotic stimulus | 121/4623 | 331/18723 | 8.45e-07 | 2.20e-05 | 121 |
GO:010400417 | Oral cavity | LP | cellular response to environmental stimulus | 121/4623 | 331/18723 | 8.45e-07 | 2.20e-05 | 121 |
GO:003049011 | Oral cavity | LP | maturation of SSU-rRNA | 28/4623 | 50/18723 | 2.17e-06 | 4.85e-05 | 28 |
GO:000931417 | Oral cavity | LP | response to radiation | 155/4623 | 456/18723 | 4.12e-06 | 8.49e-05 | 155 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa034205 | Esophagus | HGIN | Nucleotide excision repair | 29/1383 | 63/8465 | 2.96e-08 | 5.36e-07 | 4.26e-07 | 29 |
hsa0342012 | Esophagus | HGIN | Nucleotide excision repair | 29/1383 | 63/8465 | 2.96e-08 | 5.36e-07 | 4.26e-07 | 29 |
hsa0342022 | Esophagus | ESCC | Nucleotide excision repair | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa030222 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
hsa0342032 | Esophagus | ESCC | Nucleotide excision repair | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0302211 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
hsa03420 | Liver | Cirrhotic | Nucleotide excision repair | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
hsa034201 | Liver | Cirrhotic | Nucleotide excision repair | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
hsa034202 | Liver | HCC | Nucleotide excision repair | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
hsa034203 | Liver | HCC | Nucleotide excision repair | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
hsa034204 | Oral cavity | OSCC | Nucleotide excision repair | 49/3704 | 63/8465 | 3.48e-08 | 2.91e-07 | 1.48e-07 | 49 |
hsa03022 | Oral cavity | OSCC | Basal transcription factors | 28/3704 | 45/8465 | 9.53e-03 | 2.11e-02 | 1.08e-02 | 28 |
hsa0342011 | Oral cavity | OSCC | Nucleotide excision repair | 49/3704 | 63/8465 | 3.48e-08 | 2.91e-07 | 1.48e-07 | 49 |
hsa030221 | Oral cavity | OSCC | Basal transcription factors | 28/3704 | 45/8465 | 9.53e-03 | 2.11e-02 | 1.08e-02 | 28 |
hsa0342021 | Oral cavity | LP | Nucleotide excision repair | 37/2418 | 63/8465 | 5.14e-07 | 6.33e-06 | 4.08e-06 | 37 |
hsa0342031 | Oral cavity | LP | Nucleotide excision repair | 37/2418 | 63/8465 | 5.14e-07 | 6.33e-06 | 4.08e-06 | 37 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GTF2H5 | SNV | Missense_Mutation | rs114381286 | c.127G>A | p.Val43Ile | p.V43I | Q6ZYL4 | protein_coding | tolerated(0.38) | benign(0.12) | TCGA-AJ-A3TW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GTF2H5 | SNV | Missense_Mutation | novel | c.96N>T | p.Lys32Asn | p.K32N | Q6ZYL4 | protein_coding | deleterious(0.03) | possibly_damaging(0.774) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
GTF2H5 | SNV | Missense_Mutation | c.152N>G | p.Asn51Ser | p.N51S | Q6ZYL4 | protein_coding | tolerated(0.69) | benign(0.005) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
GTF2H5 | SNV | Missense_Mutation | c.106N>G | p.Gln36Glu | p.Q36E | Q6ZYL4 | protein_coding | tolerated(0.16) | benign(0.01) | TCGA-CN-A6V1-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Immunotherapy | erbitux | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |